Stent graft device for lesions of the ascending aorta
Tests a stent graft for aortic aneurysm and dissection in adults.
Key facts
- Who runs it
- W.L.Gore & Associates
- Where
- Ann Arbor, Atlanta, Aurora, Austin, Baltimore, Birmingham, Boston, Chapel Hill, Charleston, Charlotte, Chicago, Cleveland, Columbus, Durham, Falls Church, Gainesville, Grand Rapids, Hackensack, Hartford, Houston, Indianapolis, Long Beach, Los Angeles, Madison, Milwaukee, Morgantown, Murray, Norfolk, Philadelphia, Pittsburgh, Plano, Portland, Rochester, Seattle, St Louis, Stanford, Tampa, Valhalla, Washington D.C., and Wynnewood, United StatesSee the 41 sites
- Trial code
- Registry title
- Evaluation of the GORE® Ascending Stent Graft
- Status
- Enrolling by invitation
- People taking part
- 370 people, planned
- Started
- 28 Nov 2023
- Expected to end
- Jan 2034
- Type of study
- Interventional, 3 groups
- Treatments tested
- GORE® Ascending Stent Graft (ASG device)
- GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)
- Surgery
- Record updated
- 29 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a damaged ascending aorta or aortic arch (the main artery leaving the heart) who face high risk from open surgery. It tests the GORE® Ascending Stent Graft, a tube placed inside the artery, used alone or with the TBE Device.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Aneurysm (bulge) of the ascending aorta or arch: fusiform ≥50mm (≥55 mm in the ASG + TBE arm) or growth >0.5cm/year, saccular aneurysm, pseudoaneurysm >30 days after surgery, or penetrating aortic ulcer. The ASG + TBE arm also takes chronic Type A dissection (>90 days) or leftover dissection >30 days after surgery. People must be high-risk for open surgery: ≥75 years of age, a previous median sternotomy (chest opened through the breastbone), or other risk factors. The artery shape must fit the device.
- Earlier treatment
- No open chest surgery, aortic valve repair or replacement, or coronary artery procedure within 30 days before treatment. No earlier stent repair with a non-Gore device that would get in the way.
Main reasons for not taking part
- New Type A dissection (in the ASG + TBE arm: less than 90 days old), or need for immediate treatment
- Stroke or heart attack within 6 weeks before treatment
- Kidney failure with eGFR <30 (mL/min/1.73 m2) or on dialysis
- Connective tissue disease such as Marfan or Ehlers-Danlos syndrome, or an infected aorta
- Pregnant at the time of the procedure, or life expectancy <12 months
The registry criteria, word for word
Show all 75 criteriaShow less
Who can take part
- The patient is/has:
- Ascending Aortic pathologies warranting surgical repair compatible with the treatment requirements of the ASG device meeting any of the following criteria: Aneurysm; Fusiform aneurysm (≥50mm or documented growth rate >0.5cm/year); Saccular aneurysm (no diameter criteria); Pseudoaneurysms (>30 days post-surgery, no diameter criteria) Non-aneurysm; Penetrating Aortic Ulcers (PAUs) (no diameter criteria); Pseudoaneurysms, following open surgical repair of a Type A dissection (>30 days post-surgery, no diameter criteria)
- Anatomic compatibility with ASG device based on Gore Imaging Sciences review; Treatment must be limited to the ascending aorta; Lesion location is ≥2cm distal to the most distal coronary artery ostia; Distal extent of the lesion is located ≥2cm proximal to the origin of the Brachiocephalic Artery (BCA); Proximal and distal landing zones must be ≥2cm in length; Landing zones cannot be heavily calcified, or heavily thrombosed; Landing zone diameter between 27mm - 48mm; For patients with prior replacement of the ascending aorta and/or aortic arch by an endovascular or surgical graft, there must be at least ≥2 cm overlap of ASG device and previously implanted graft
- Considered high-risk for open surgical repair by meeting any of the following criteria:; ≥75 years of age; Previous median sternotomy; Documented identification of other subject-specific risk factors (e.g., medical history, active medical diagnosis) by a study investigator and an experienced open ascending and/or aortic arch surgeon (e.g., cardiothoracic surgeon)
- Age ≥18 years at time of informed consent signature
- Adequate vascular access via transfemoral or retroperitoneal approach
- Informed Consent Form (ICF) signed by the subject or legally authorized representative
- Agrees to comply with protocol requirements, including imaging and 5-year follow-up
- The patient is/has:
- Ascending and/or Arch Aortic pathologies warranting surgical repair compatible with the treatment requirements of the ASG device and meeting any of the following criteria: Aneurysms; Fusiform aneurysm (≥55 mm or documented growth rate >0.5cm/year); Saccular aneurysm (no diameter criteria); Pseudoaneurysms (>30 days post-surgery, no diameter criteria) Non-aneurysms; Penetrating Aortic Ulcers (no diameter criteria); Pseudoaneurysms, following open surgical repair of a Type A dissection (>30 days post-surgery, no diameter criteria); Chronic de novo (>90 days) Type A aortic dissection requiring treatment; Chronic de novo aortic dissection with primary entry tear in the ascending aorta or arch; Chronic de novo aortic dissection with primary entry tear in the descending thoracic aorta with retrograde involvement of the aortic arch and/or ascending aorta; Residual aortic dissection following surgical repair of Type A aortic dissection requiring treatment (>30 days post-surgery)
- Anatomic compatibility with ASG device used in combination with the TBE Device based on Gore Imaging Sciences review; Proximal Aortic Landing Zone:; Landing zone is native aorta or surgical graft; Lesion location is ≥2cm distal to the most distal coronary artery ostia; Proximal landing zone must be ≥2cm in the ascending aorta; Landing zone cannot be aneurysmal, heavily calcified, or heavily thrombosed; Landing zone diameter between 27mm - 48mm; Acceptable proximal landing zone outer curvature length for the required device; Branch Vessel Landing Zone:; Length of ≥2.5 cm proximal to first major branch vessel; Target branch vessel inner diameters of 11-18 mm; Target branch vessel landing zone must be in native vessel that cannot be heavily calcified, or heavily thrombosed; Distal Aortic Landing Zone:; Outer curvature must be ≥2 cm proximal to the celiac artery; Aortic inner diameters between 16-42 mm; Landing zone in native aorta or previously implanted GORE® TAG® Conformable Thoracic Stent Graft (CTAG Device)
- Considered high-risk for open surgical repair by meeting any of the following criteria:; ≥75 years of age; Previous median sternotomy; Documented identification of other subject-specific risk factors (e.g., medical history, active medical diagnosis) by a study investigator and an experienced open ascending and/or aortic arch surgeon (e.g., cardiothoracic surgeon)
- Age ≥18 years at time of informed consent signature
- Adequate vascular access via transfemoral or retroperitoneal approach
- Informed Consent Form (ICF) signed by the subject or legally authorized representative
- Agrees to comply with protocol requirements, including imaging and 5-year follow-up
- Subjects who meet the following criteria will be followed:
- The aortic lesion involves the ascending aorta and/or aortic arch
- The subject is determined to be high-risk for open surgical repair per the protocol requirements
- The subject is at least 18 years of age
- The subject is willing to comply with the protocol requirements
- Open surgery to repair the aortic lesion the patient was screened for is intended to be performed at the investigational site responsible for initiating the screening process for the study
Who cannot take part
- Any aortic valve repair or replacement including transcatheter aortic valve replacement (TAVR) or coronary artery intervention within 30 days prior to treatment
- Open chest surgical repair within 30 days prior to treatment
- Previous endovascular repair with a non-Gore device that would interfere with or result in contact with planned repair
- Concomitant vascular disease requiring treatment that is not planned for index endovascular procedure
- Any stroke or myocardial infarction within 6 weeks prior to treatment
- Participation in investigational drug or medical device study within one year of enrollment unless approved by the sponsor
- Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication)
- Any aortic valve repair or replacement including transcatheter aortic valve replacement (TAVR) or coronary artery intervention within 30 days prior to treatment
- Open chest surgical repair within 30 days prior to treatment
- Previous endovascular repair with a non-Gore device that would interfere with or result in contact with planned repair
- Concomitant vascular disease requiring treatment that is not planned for index endovascular procedure
- Any stroke or myocardial infarction within 6 weeks prior to treatment
- Participation in investigational drug or medical device study within one year of enrollment unless approved by the sponsor
- Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication)
- Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin or a history of a hypercoagulability disorder and/or state
- Prosthetic heart valve in the aortic position that precludes safe delivery of the ASG device
- Aortic insufficiency grade 3 or greater
- Presence of protruding and/or irregular thrombus and/or atheroma in the ascending aorta or aortic arch or any other factors that could increase the risk of stroke based on imaging review
- Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome, EDS)
- Known history of drug abuse within one year of treatment
- Active infected aorta, mycotic aneurysm
- Known sensitivities or allergies to the device materials
- Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
- Body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta
- Prosthetic heart valve in the aortic position that precludes safe delivery of the ASG device
- Aortic insufficiency grade 3 or greater
- Presence of protruding and/or irregular thrombus and/or atheroma in the ascending aorta or aortic arch or any other factors that could increase the risk of stroke based on imaging review
- Known degenerative connective tissue disease (e.g., Marfan Syndrome or Ehlers-Danlos Syndrome, EDS)
- Known history of drug abuse within one year of treatment
- Active infected aorta, mycotic aneurysm
- Known sensitivities or allergies to the device materials
- Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
- Body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta
- Complex percutaneous coronary intervention (PCI) or treatment for acute coronary syndrome requiring Dual Anti Platelet Therapy (DAPT) within 30 days prior to treatment
- Renal failure, defined as patients with an estimated Glomerular Filtration Rate (eGFR) <30 (mL/min/1.73 m2) or currently requiring dialysis
- Complex percutaneous coronary intervention (PCI) or treatment for acute coronary syndrome requiring Dual Anti Platelet Therapy (DAPT) within 30 days prior to treatment
- Renal failure, defined as patients with an estimated Glomerular Filtration Rate (eGFR) <30 (mL/min/1.73 m2) or currently requiring dialysis
- The patient is/has:
- De novo Type A dissection
- Requires immediate treatment
- Dissected great vessels requiring treatment
- Anticipated need for coronary or aortic valve intervention within one year post treatment
- Presence of Intramural Hematoma (IMH) in landing zones
- Pregnant at time of procedure
- Life expectancy <12 months
- The patient is/has:
- Acute and subacute de novo Type A dissection (defined as <90 days)
- Requires immediate treatment
- Dissected great vessels requiring treatment
- Anticipated need for coronary or aortic valve intervention within one year post treatment
- Presence of Intramural Hematoma (IMH) in landing zones
- Pregnant at time of procedure
- Life expectancy <12 months
Where in United States
- University of Michigan Frankel Cardiovascular CenterAnn Arbor, United StatesEnrolling by invitation
- Emory University HospitalAtlanta, United StatesEnrolling by invitation
- University of Colorado Hospital AuthorityAurora, United StatesEnrolling by invitation
- Cardiothoracic and Vascular SurgeonsAustin, United StatesEnrolling by invitation
- University of Maryland Medical CenterBaltimore, United StatesEnrolling by invitation
- University of Alabama at BirminghamBirmingham, United StatesEnrolling by invitation
- Massachusetts General HospitalBoston, United StatesEnrolling by invitation
- University of North Carolina at Chapel HillChapel Hill, United StatesEnrolling by invitation
- Medical University of South CarolinaCharleston, United StatesEnrolling by invitation
- Atrium HealthCharlotte, United StatesEnrolling by invitation
- Northwestern University -Bluhm Cardiovascular Institute, Clinical Trials UnitChicago, United StatesEnrolling by invitation
- Cleveland Clinic FoundationCleveland, United StatesEnrolling by invitation
- OhioHealth Research and Innovation InstituteColumbus, United StatesEnrolling by invitation
- Duke University Medical CenterDurham, United StatesEnrolling by invitation
- Inova Fairfax Medical CampusFalls Church, United StatesEnrolling by invitation
- University of Florida - GainesvilleGainesville, United StatesEnrolling by invitation
- Corewell HealthGrand Rapids, United StatesEnrolling by invitation
- Hackensack UMCHackensack, United StatesEnrolling by invitation
- Hartford HospitalHartford, United StatesEnrolling by invitation
- Methodist DeBakey Heart & Vascular CenterHouston, United StatesEnrolling by invitation
- Indiana University School of MedicineIndianapolis, United StatesEnrolling by invitation
- MemorialCare Heart and Vascular Institute - Long Beach Medical CenterLong Beach, United StatesEnrolling by invitation
- Cedars-Sinai Medical CenterLos Angeles, United StatesEnrolling by invitation
- Keck Medical Center University of Southern California, HCC IILos Angeles, United StatesEnrolling by invitation
- University of Wisconsin Hospital & ClinicsMadison, United StatesEnrolling by invitation
- Medical College of WisconsinMilwaukee, United StatesEnrolling by invitation
- West Virginia University MedicineMorgantown, United StatesEnrolling by invitation
- Intermountain Heart InstituteMurray, United StatesEnrolling by invitation
- Sentara Mid Atlantic Cardiothoracic SurgeonsNorfolk, United StatesEnrolling by invitation
- University of PennsylvaniaPhiladelphia, United StatesEnrolling by invitation
- University of Pittsburgh Medical CenterPittsburgh, United StatesEnrolling by invitation
- The Heart Hospital at Baylor PlanoPlano, United StatesEnrolling by invitation
- Oregon Health and Science UniversityPortland, United StatesEnrolling by invitation
- Mayo Clinic - RochesterRochester, United StatesEnrolling by invitation
- University of Washington Medical CenterSeattle, United StatesEnrolling by invitation
- Washington University School of Medicine - St. LouisSt Louis, United StatesEnrolling by invitation
- Stanford HospitalStanford, United StatesEnrolling by invitation
- University of South FloridaTampa, United StatesEnrolling by invitation
- Westchester Medical CenterValhalla, United StatesEnrolling by invitation
- MedStar Washington Hospital CenterWashington D.C., United StatesEnrolling by invitation
- Lankenau Institute for Medical ResearchWynnewood, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The primary objective of ARISE II is to assess the safety and effectiveness of the GORE® Ascending Stent Graft device in the treatment of lesions involving the ascending aorta and aortic arch.
The 3 groups in the trial
- ASG device only in Ascending AortaTreatment being tested
Ascending Aortic Isolated Lesions, Pseudoaneurysms and Penetrating Aortic Ulcers in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG device alone.
Treatment: GORE® Ascending Stent Graft (ASG device)
- ASG + TBETreatment being tested
Ascending Aorta/Aortic Arch Isolated Lesions and Chronic De Novo Dissections in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG and TBE devices.
Treatment: GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)
- Surgical Follow-up CohortOther group
Open surgical repair of ascending aorta in subjects at high-risk for surgical repair
Treatment: Surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the GORE® Ascending Stent Graft in the Treatment of Lesions of the Ascending Aorta
- Plain-language title
- Stent graft device for lesions of the ascending aortaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 May 2026